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OBTAIN REQUIRED DOSES TO INFORM USE OF MANIPULATION IN PAEDIATRIC 2 
PRACTICE. 3 
 4 
AUTHORS 5 
Roberta H. Richey [1, 2] PhD, MRes, BSc, RGN. (roberta.richey@thewaltoncentre.nhs.uk ) 6 
Clare Hughes [3] MPharmS. 7 
Jean V. Craig [4] PhD, RSCN, RGN. (Jean.Craig@uea.ac.uk ) 8 
Utpal U. Shah [1, 3, 5] PhD, MPharm.  9 
James L. Ford [3] BSc, PhD, FRPharmS, FRSC. (j.l.ford@ljmu.ac.uk ) 10 
Catrin E. Barker [1, 5] MSc, PGDipClinPharm, MRPharmS. (catrin.barker@alderhey.nhs.uk ) 11 
Matthew Peak [1, 5] PhD, MSc, BSc. (Matthew.Peak@alderhey.nhs.uk ) 12 
Anthony J. Nunn [1, 3, 6] BPharm, FRPharmS, Hon FRCPCH. (a.j.nunn@liverpool.ac.uk ) 13 
Mark A. Turner [6, 7] PhD, MBChB, MRCPCH. (mark.turner@liverpool.ac.uk) 14 
 15 
[1] Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, L12 2AP 16 
[2] The Walton Centre NHS Foundation Trust, Liverpool, L9 7LJ  17 
[3] School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Byrom 18 
Street, Liverpool, L3 3AF 19 
[4] Norwich Medical School, Faculty of Medicine and Health Sciences, University of East 20 
Anglia, Norwich Research Park, Norwich, NR4 7TJ 21 
[5] Cheshire, Merseyside & North Wales Medicines for Children Local Research Network, 22 
Eaton Road, Liverpool, L12 2AP 23 
[6] NIHR Medicines for Children Research Network Co-ordinating Centre, Institute of Child 24 
Health, University of Liverpool, L12 2AP 25 
[7] Liverpool Women‟s Hospital NHS Foundation Trust, Crown Street, Liverpool, L8 7SS 26 
 2 
 27 
Corresponding author:  Professor James Ford, email: j.l.ford@ljmu.ac.uk 28 
Conflict of interest statement: The authors have no conflict of interest to report.  29 
 30 
Funding statement: This paper presents independent research commissioned by the National 31 
Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme 32 
(Grant Reference Number PB-PG-0807-13260). The views expressed are those of the authors 33 
and not necessarily those of the NHS, the NIHR or the Department of Health. 34 
 35 
  3 
ABSTRACT 36 
This study sought to determine whether there is an evidence base for drug manipulation to obtain 37 
the required dose, a common feature of paediatric clinical practice. A systematic review of the 38 
data sources, PubMed, EMBASE, CINAHL, IPA and the Cochrane database of systematic 39 
reviews, was used. Studies that considered the dose accuracy of manipulated medicines of any 40 
dosage form, evidence of safety or harm, bioavailability, patient experience, tolerability, 41 
contamination and comparison of methods of manipulation were included. Case studies and 42 
letters were excluded. Fifty studies were eligible for inclusion, 49 of which involved tablets 43 
being cut, split, crushed or dispersed. The remaining one study involved the manipulation of 44 
suppositories of one drug. No eligible studies concerning manipulation of oral capsules or 45 
liquids, rectal enemas, nebuliser solutions, injections or transdermal patches were identified. 46 
Twenty four of the tablet studies considered dose accuracy using weight and/or drug content. In 47 
studies that considered weight using adapted pharmacopoeial specifications, the percentage of 48 
halved tablets meeting these specifications ranged from 30% to 100%. Eighteen studies 49 
investigated bioavailability, pharmacokinetics or clinical outcomes following manipulations 50 
which included nine delayed or modified release formulations. In each of these nine studies the 51 
entirety of the dosage form was administered. Only one of the 18 studies was identified where 52 
drugs were manipulated to obtain a proportion of the dosage form, and that proportion 53 
administered. The five studies that considered patient perception found that having to manipulate 54 
the tablets did not have a negative impact on adherence. Of the 49 studies only two studies 55 
reported investigating children. This review yielded limited evidence to support manipulation of 56 
medicines for children. The results cannot be extrapolated between dosage forms, methods of 57 
manipulation or between different brands of the same drug. 58 
59 
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INTRODUCTION  60 
Many medicines given to children are used „off-label‟ because the medicine has only been 61 
researched and authorised for adults. Often the dosage form (e.g., tablets, capsules, 62 
suppositories) is suitable for administration to adults but not to younger children (Waller, 2007). 63 
Age-appropriate formulations may not be commercially available to provide the wide range of 64 
doses required for neonatal and paediatric use (Olski et al, 2011; Fontan et al 2004; Nahata, 65 
1999). In order to tackle these problems medicines are routinely modified, whereby the dosage 66 
form is physically manipulated with the aim of achieving the required dose for administration. 67 
Differing definitions of „modification‟ and „manipulation‟ have been used (EMA 2013, Ernest et 68 
al, 2012). In the context of this study, a manipulation is defined as the physical alteration of a 69 
drug dosage form for the purpose of extracting and administering the required proportion of the 70 
drug dose. This work does not consider manipulations done for convenience or due to patient 71 
preference. 72 
The Pharmaceutical industry invests considerable time and financial resource in the development 73 
of products designed for accurate and appropriate drug delivery. Legislation, in the form of the 74 
European Union Paediatric Regulation (2007) was established to drive the development of 75 
appropriately licensed and formulated medicines for children, through a system of requirements 76 
and incentives. Simultaneously the World Health Organisation (WHO, 2007) spearheaded a 77 
global campaign to raise awareness and accelerate action to address the need for improved 78 
availability and access to safe, child-specific medicines for all children under 12 years of age. 79 
Similar legislation has been enacted in the US (Turner et al, 2014). 80 
However, it will be some time before the influence of this legislation and campaign strategy is 81 
realized and suitably formulated medicines are made available for children. Even when age-82 
appropriate formulations are marketed, the need for manipulations will remain as drug 83 
development is not able to take account of all the possible circumstances of drug administration. 84 
Table 1 provides examples of the type of dosage form manipulation used with the aim of 85 
achieving the required dose. Although drug manipulation is an acknowledged feature of 86 
paediatric clinical practice (Nunn, 2003), and a quantitative description of the situation in the UK 87 
in 2011 has been described (Richey et al, 2013a), previous studies have noted that there is a lack 88 
of information available on the extent to which manipulated drugs are being used (Skwierczynski 89 
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& Conroy, 2008; Conroy et al, 2000). Manipulations, such as halving tablets to obtain two doses, 90 
are used as a cost reduction measure in some jurisdictions (Berg & Ekedahl, 2010; Gee et al, 91 
2002; Fawell et al, 1999). In other vulnerable groups such as the elderly, those on intensive care 92 
and those receiving enteral feeds, manipulation is common to aid administration (Berg & 93 
Ekedahl, 2010; Gerber et al, 2008; Paradiso et al, 2002; Verrue et al, 2010). Whole tablets may 94 
be crushed and capsules opened and mixed with food or drinks to aid administration to children. 95 
Manipulations are time consuming, may be inaccurate, and the effects on the stability and 96 
bioavailability of the drug may be unknown (Skwierczynski & Conroy, 2008). It is thus possible 97 
to inadvertently administer toxic or sub-therapeutic doses. Manipulations may also increase the 98 
risk of drug errors because calculations are required to determine an amount to be administered 99 
and dose calculation errors at the point of administration have been identified as the most 100 
common type of medication error in neonatal and paediatric patients (Chua, 2010; Conroy et al, 101 
2007). Concerns about dose accuracy in other patient groups have also been highlighted (Berg & 102 
Ekedahl, 2010; Verrue et al, 2010). 103 
This review focuses on manipulations conducted with the aim of obtaining the required dose. 104 
Given the lack of age appropriate doses or dosage forms for many drugs, the investigators are 105 
particularly interested in manipulations of drugs for paediatric and neonatal use. However, there 106 
may be situations where drugs relevant to paediatric practice are manipulated, for older patients. 107 
The aim of this systematic review is to establish the evidence base for drug manipulation to 108 
obtain the required dose. 109 
METHODS  110 
The systematic review protocol, including details of the iterative approach to developing the 111 
search strategy and refinement of a quality appraisal tool, has been previously published (Richey 112 
et al, 2012) The review was designed and completed with the support and advice of a steering 113 
group consisting of experts in formulation, research, medicine, pharmacy and nursing. 114 
Eligibility criteria 115 
This review excluded case studies, case reports and letters; it did not otherwise restrict on study 116 
design. Evidence was also taken from studies where drug manipulation was investigated without 117 
administration to patients as these laboratory-based studies considered the weight and/or drug 118 
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content of manipulated drugs. Studies investigating any drug, manipulated by any method were 119 
potentially eligible.  120 
A hierarchy of outcomes was identified. The primary outcome was dose accuracy of the 121 
manipulated medicine as assessed by drug content assay or other relevant study specific methods 122 
such as weight. Secondary outcomes included: evidence of safety or harm (which the authors 123 
explicitly attribute to the manipulation); bioavailability, physical/chemical/microbial stability; 124 
patient experience of drug manipulation; tolerability/palatability/adherence (explicitly attributed 125 
to the manipulation); contamination of the areas of the manipulation/healthcare 126 
professional/patients/carer and any comparison of methods of manipulation used on similar 127 
dosage forms. 128 
Manipulation of a medicine with subsequent administration of the entire dosage form was 129 
considered outside the remit of this review. An exception to this was tablets with a modified-130 
release design. Where tablets have a modified-release design, crushing, splitting or dispersing of 131 
these tablets, may alter the bioavailability and safety of these tablets, even when the entire 132 
dosage form is administered. Studies that involved extemporaneous or compounding preparation 133 
within a pharmacy and those which were involved in the drug development process were 134 
excluded. 135 
Information sources and searches  136 
The Cochrane database of systematic reviews, MEDLINE (Internet interface PubMed), 137 
EMBASE, CINAHL and International Pharmaceutical Abstracts (IPA) databases were searched 138 
from inception of data base to August 2015. The review steering group and research and 139 
healthcare practitioners with expertise in medicines management were asked to provide 140 
references to any additional studies or unpublished data. The reference lists of included studies 141 
were checked for any additional eligible studies. The devising of the search strategy was 142 
complex as any drug or dosage form was potentially eligible. Furthermore manipulation to obtain 143 
the required dose does not have a standard term in databases of the medical and pharmaceutical 144 
literature therefore a list of free text descriptions for manipulation had to be identified. As the 145 
search strategy underwent a considerable review and revision process (Richey et al, 2012) a 146 
balance had to be made between the sensitivity and the precision of the search with the 147 
consequential risk that there may be studies that have not been identified. Therefore subsequent 148 
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narrower search strategies for three of the known manipulated drugs (omeprazole, captopril and 149 
warfarin) were devised and searches completed. The generic strategy has been described in the 150 
appendix of the published protocol (Richey et al, 2012). Initial searches were completed in 151 
August 2009; update searches were completed in August 2015. 152 
Study selection and data extraction  153 
Due to the considerable number of records identified by the generic search (39,762 hits) and the 154 
narrower drug-specific searches (4535 hits) an initial screen was undertaken by one reviewer 155 
(Richey et al 2012). A random sample of 5% the titles and abstracts was screened by a second 156 
reviewer to confirm the initial screening. Potentially eligible studies identified from the initial 157 
screen were independently considered and discussed by two reviewers and the full text of 158 
potentially eligible studies obtained. A third reviewer was available for any studies where 159 
agreement on inclusion could not initially be reached. Data for the included studies were 160 
extracted into data extraction tables by one reviewer, these were then independently assessed by 161 
the second reviewer and changes agreed. Drug specific searches did not yield any additional 162 
studies. 163 
Quality assessment 164 
An assessment of risk of bias of included studies was carried out at study, rather than outcome 165 
level using a bespoke quality assessment form derived from established checklists and 166 
supplemented with review specific criteria compiled by formulations, systematic review and 167 
healthcare professional experts (Richey et al, 2012). Two reviewers assessed studies 168 
independently and then discussed their decision-making to reach agreement on the quality 169 
criteria for the included studies. Overall quality ratings were then assigned to the studies using 170 
the symbols ++, + and – as described in Table 1. The authors, during the review processes, 171 
assessed the confidence/trust that can be placed on the outcomes of the studies. Thus in Table 1 172 
considerable concerns” represents studies where a lot of risk of bias was apparent in the study 173 
design/methods or reported results/outcomes and meant that the study was considered as 174 
potentially unreliable. “Some concerns” indicates that some risk of bias in the design/methods 175 
was recognised that raised questions about the reliability of the reported results/outcomes. “With 176 
reasonable confidence” implies that the study design/methods are considered to have a lower risk 177 
of bias and the results/outcomes reported can be considered reliable.  178 
  8 
 179 
Data synthesis 180 
In order to capture as much data as possible that is relevant to clinical practice there was no 181 
restriction on study design, type of drug or method of manipulation. Accordingly, this review 182 
includes a heterogeneous set of studies. Because the studies were so heterogeneous, a narrative 183 
synthesis of the findings was used with no meta-analysis; the data from each study were 184 
extracted and tabulated, with studies grouped using the primary and secondary outcomes defined 185 
for this review. Results are generally presented descriptively 186 
 187 
RESULTS AND DISCUSSION  188 
Fifty studies were included and quality-assessed. Twelve (24%) studies were assigned a ++ 189 
quality rating, 30 (60%) studies a + rating and 8 (16%) a – rating (Table 2). 190 
Forty-nine studies were identified that met the inclusion criteria for tablets that were crushed, 191 
split or dispersed. These included 24 studies that had outcomes that included an assessment of 192 
the weight of split portions and/or their drug content and 10 studies that compared different 193 
methods of manipulation. Five studies had acceptance outcomes and included patient issues such 194 
as patient experience, adherence, taste or tolerability; nine studies had bioavailability outcomes. 195 
Though adverse effects are reported in the bioavailability studies there were no studies that 196 
specifically considered evidence of the safety or harm of manipulating medicines.  197 
Primary outcome: dose accuracy of the manipulated medicines – weight and/or drug content 198 
outcomes  199 
The dose accuracy of manipulated medicines was assessed by different studies through weight, 200 
dissolution profiles and/or drug content outcomes. In the absence of pharmacopoeial tests to 201 
establish uniformity of split tablets at the time that many of these studies were undertaken, some 202 
authors devised tests adapted from the then current pharmacopoeial criteria for intact (whole) 203 
dosage forms. These criteria mimic those currently found in the British Pharmacopoeia (2016) 204 
where tablets bearing break-marks that allow subdivision to provide required dose can be 205 
assessed. The efficacy of the break-mark(s) must be assessed during the development in respect 206 
of uniformity of mass of the subdivided parts. The test is based on 30 randomly selected tablets 207 
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which are broken by hand; one part is taken from each of the subdivided tablets and weighed. 208 
Each part is individually weighed and the average mass calculated. Compliance is agreed if not 209 
more than 1 individual mass is outside the limits of 85% to 115% of the average mass and that 210 
individual mass is not outside the limits of 75% to 125% of the average mass. 211 
There were 24 studies that assessed the physical characteristics of halved tablets; 18 studies 212 
halved tablets and used adapted pharmacopoeial criteria. It might be assumed that any split 213 
fragment of a tablet will contain the fraction of the initial content proportional to the ratio of the 214 
fragment weight: whole tablet weight. Analysis of mercaptopurine tablets showed this to be the 215 
case (Footitt, 1983). However analysis of fragments from levodopa tablets (Walker et al, 1978) 216 
showed a highly significant difference in the variation of percentage of drug content between 217 
quarters and tablets. 218 
Table 3 provides a summary of eight studies that were identified as assessing halved or quartered 219 
tablets using pharmacopoeial-based outcomes for weight and/or drug content uniformity. There 220 
is no assurance that halving or quartering tables provides uniform split products  221 
One study (Horn et al, 1999) halved and quartered tablets and used pharmacopoeial-based 222 
outcomes for weight and/or drug content uniformity to compare two tablet splitters. Seven 223 
products were examined. These were scored clonidine (branded and generic), scored captopril, 224 
unscored amlodipine, unscored atenolol, scored sertraline and scored carbamazepine. Tablets 225 
from lots of each product were halved and quartered and assessed by weighing within ±15%, 226 
USP specification. The data in Table 4 clearly indicate the difference in batch performance, that 227 
different quality of portions may be obtained from different splitters and that the variation in 228 
quarters is greater than that for halved tablets. 229 
In another study Stimpel et al (1985) halved 34 products which were scored tablets and 230 
contained antihypertensive drugs. The tablets were described as displaying excellent divisibility 231 
(7 products), good divisibility (11 products), moderate divisibility (10 products) or poor 232 
divisibility (6 products). One commercial controlled release tablet containing isorbide-5-233 
mononitrate tablet of 60 mg is scored and designed to allow division into 20mg and 40 mg 234 
segments (Stockis et al, 2002) 235 
Splitting tablets into two or three parts was reproducible with relative standard deviations of 0.8 236 
– 1.5 %. The presence of a score line does not guarantee an even subdivision of tablets (Footitt, 237 
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1983; Hill et al, 2009; Polli et al, 2003; Rashed et al, 2003; Rosenberg et al, 2002; Teng et al, 238 
2002; Zaid & Ghosh, 2011; Horn et al, 1999) (Table 3). Uniform splitting was related to the 239 
hardness, friability and shape of tablets (Zaid & Ghosh, 2011). 240 
Splitting was also related to tablet shape, size & hardness and the depth of score lines. Tahaineh 241 
& Gharaibeh (2012) split tablets (four products) with a knife and assessed the resulting half-242 
tablets for weight uniformity using an adapted USP method. Split warfarin tablets were uniform 243 
in weight- which was attributed to hardness and the presence of a deep score line. Splitting 244 
digoxin, phenobarbital, and prednisolone tablet produced half tablets whose weights were highly 245 
variable (Tahaineh & Gharaibeh, 2012). Splitting sixteen tablet products with a knife was 246 
assessed by Helmy (2015) using weight and content uniformity of half tablets. Dose variation 247 
exceeded a proxy USP specification for more than one-third of sampled half tablets of 248 
bromazepam, carvedilol, bisoprolol, and digoxin. Drug content in half tablets appeared to be due 249 
to weight variation due to fragment or powder loss during the splitting process. Tablet size, 250 
shape, hardness and presence of score lines were important variables. Quality control standards, 251 
other than mass uniformity and drug content may be used to assess the physical quality of 252 
manipulated tablets. Vranic & Uzunovic (2008) found that scored whole and halved tablets of 253 
four lisinopril products met Ph Eur adapted specifications for crushing strength, friability, 254 
disintegration time and mass uniformity. Costa et al (2000) halved and quartered three products 255 
containing captopril finding their hardnesses ranked as whole > halved > quartered tablets. 256 
A variety of studies has extended splitting to include quartered tablets. The studies of Tuleu et al 257 
(2005) and Horn et al (1999) are discussed in Table 3 and below. Costa et al (2000) extended 258 
their studies into three captopril products and devised a divisibility assay value which was 259 
defined as the percent standard deviation divided by mean half or quarter weights, in effect a 260 
relative standard deviation. Values were 7.7. 5.8 and 8.3% for halves and 15.0, 8.8 and 16.9% for 261 
quarters for the three captopril products indicating decreased consistency of weight for quartered 262 
compared with halved tablets. In another study, Walker et al (1978) quartered tablets and 263 
considered that two products, each containing levodopa, showed no significant difference in 264 
weight variation between whole tablets and quarters whilst another levodopa product and a 265 
sulphamethoxypyridazine tablet showed significant difference in weight variation between whole 266 
tablets and quarters. For one of the levodopa products, significant difference in percentage 267 
content between tablets and quarters implied less homogeneity of drug distribution in un-268 
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quartered tablets (Walker et al, 1978). 269 
Eight studies (Costa et al, 2000; Erramouspe & Jarvi, 1997; Kayitare et al, 2009; Mandal, 1996; 270 
Shah et al, 1987; Simons et al, 1982; Stockis et al, 2002; Tuleu et al, 2005) used dissolution 271 
profiles to assess halved or segmented tablets. Each study identified differences in dissolution 272 
profiles between halved and intact tablets, and, with the exception of the work of Costa et al 273 
(2000), considered tablets with a modified-release mechanism. This latter study, examining three 274 
captopril products demonstrated that halving and quartering the tablets increased the speed of 275 
dissolution for the three tablets (Costa et al, 2000). Halved or quartered nifedipine modified 276 
release tablets had faster dissolution profiles than intact tablets (Tuleu et al, 2005). 277 
Dissolution profiles of tablet fragments of Isorbide-5-mononitrate 60mg tablets differed by 10% 278 
or less relative to intact tablets (Stockis et al, 2002). Mean cumulative dissolution profiles of 279 
extended release methylphenidate tablets showed significant differences between halved and 280 
whole tablets from the same manufacturers and between halved brand and whole generic tablets 281 
(Erramouspe & Jarvi, 1997). Comparing the release of three aspirin products (sustained-release 282 
aspirin 800mg, , aspirin 325mg, extended-release aspirin 650mg, microencapsulated particles), 283 
Mandal (1996) showed that the dissolution rate of the split tablets of the 800mg tablets was 284 
significantly higher than that for whole tablets although the other tablets had similar drug release 285 
profiles over time with whole and split tablets. Brands of theophylline 300mg controlled-release 286 
had significantly different dissolution profiles between whole and half tablets in simulated 287 
gastric fluid and simulated intestinal fluid (Shah et al, 1987). Dissolution from halved sustained 288 
release theophylline 100mg tablets was significantly higher than from whole tablets (Simons et 289 
al, 1982) 290 
Kayitare et al (2009) developed a novel fixed dose combination tablet, containing 300mg 291 
zidovudine and 160mg lamivudine, for paediatric HIV patients to allow easy breaking into a 292 
maximum of 8 subunits. The intact tablets and their subunits disintegrated within 20 s and in 293 
dissolution tests, > 95% of each drug was released after 30 min.  294 
Tablet shape Outcomes 295 
Six  studies (Helmy, 2015; Hill et al, 2009; Polli et al, 2003; Rosenberg et al, 2002; Teng et al, 296 
2002; Verrue et al, 2010) that included tablets which were not flat and round but were 297 
alternatively shaped (e.g., trapezoid, octagon, shield-shaped, ovoid-rectangular). Halves of these 298 
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tablets did not meet the specified USP weight specification. Another study (Zaid & Ghosh, 2011) 299 
showed that of 4 products examined, only one film-coated oblong shaped tablet passed the Ph 300 
Eur specification for weight uniformity of scored tablets whereas three other oblong-shaped 301 
tablets (one film-coated) did not. A square captopril product (Costa et al, 2000) subdivided into 302 
halves and quarters, met weight variation limits whereas two circular tablets did not, despite all 303 
three products having crossed grooves on one of their faces. 304 
A novel fixed dose combination tablet, containing 300mg zidovudine and 160mg lamivudine, 305 
was developed for paediatric HIV patients (Kayitare et al, 2009). The novel product had a 306 
rectangular shape (22.4 mm long, 11.2 mm wide) with multiple score lines (depth 0.89 mm, 307 
angle 100º) to allow easy breaking into a maximum of 8 subunits. The tablets were subdivided 308 
along the score lines into 1/2 (along shortest axis of the tablet), 1/4 (along shortest axis), 3/4 309 
(along shortest axis) and 1/8 tablet. The average weights of the smallest pieces (1/8 of a tablet) 310 
were within the 85–115% range of the average mass limits as required by EP. 311 
Tablet dispersions 312 
Apart from splitting tablets, dispersing tablets in water and taking an aliquot of the resulting 313 
suspension is used clinically to obtain reduced doses. Two studies assessed this practice using 314 
prior crushing and dispersion of nifedipine tablets (Tuleu et al, 2005) or dispersing dispersible 315 
aspirin 75 mg tablets (Broadhurst et al, 2008). Crushed nifedipine 10 mg modified release tablets 316 
were suspended in 10ml water. Samples were extracted using 1 or 5 ml oral syringes. Doses 317 
ranging from 2.9 to 5.7 mg and 0.6 to 1.5 mg were obtained using 5 ml and 1 ml syringes 318 
respectively compared to theoretical doses of 5 and 1 mg (Tuleu et al, 2005). Reproducing 319 
clinical practice, Broadhurst et al (2008) dispersed dispersible aspirin tablets in 10 mL water and 320 
found that, irrespective of dispersion time, the samples taken from the base of a 30 mL container 321 
were consistently closer to the intended dose (51-95% of the intended dose) compared with those 322 
taken from the highest zone at 8 mL mark of the container (23-80% of the intended dose), with a 323 
trend for the dose measured to decrease as the zones ascended up the beaker. 324 
 325 
Secondary outcomes: comparison between weight loss, manipulation methods, bioavailability, 326 
effectiveness, patient experience, adherence/compliance 327 
Comparison between manipulation methods:  328 
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Twelve studies were identified that compared methods of manipulating tablets (Table 5). Overall 329 
the use of a commercial tablet splitter (by some authors termed tablet cutter) was more accurate 330 
than other splitting methods such as scissors or knives, or splitting manually. 331 
Weight loss during manipulation 332 
Ten studies quantified the weight loss observed during the halving or quartering of tablets. Mean 333 
weight losses for mercaptopurine tablets varied from 0.24% to 2.64% depending on the operator, 334 
although individual losses as high as 11.7% were recorded (Footitt, 1983). Using tablet splitters, 335 
mean weight losses of between 0.1% and 1.3% were recorded for six commercial products (Hill 336 
et al, 2009) and 0% to 1.9% for 12 commercial products (Polli et al, 2003) although in the latter 337 
study a maximum weight loss of 7.3% was noted for one product and weight loss was not 338 
considered to be an indicator of the uniformity of split. Similar mean weight loss ranges were 339 
reported as 0.02% to 1.5% for 16 products (Helmy, 2015) 0.1% to 1.2% when halving or 340 
quartering captopril tablets (Costa et al, 2000) and 0.3% to 0.9% when quartering tablets made to 341 
a model formulation (van Vooren, 2002) where a maximum weight loss of 6.8% was recorded. 342 
Although a mean loss of 1.1% was noted for the loss following splitting of hydrochlorothiazide 343 
tablets (McDevitt et al, 1998), the range of loss varied from 0% to 19.4%. Recovery (in 344 
comparison to weight loss) of misoprostol tablets quartered by a pill splitter and by hand were 345 
96.6 ± 2.8% and 99.0 ± 1.3% respectively (Williams et al, 2002). The most comprehensive study 346 
(Verrue et al, 2010) compared three routine splitting methods (grouped as a splitting device, 347 
scissors or by hand, and a kitchen knife) to half or quarter eight commercial products. 348 
Statistically, the splitting device only produced the lowest weight loss of the three methods for 349 
the digoxin tablets when a mean weight loss of 1.4% was recorded as against 7.6% and 5.4% for 350 
the scissors/hand and kitchen knife respectively. For five products (warfarin, levodopa/carbidopa 351 
each halved; fenprocoumon, methylprednisolone and lisinopril, each quartered) the results 352 
obtained by the splitting device or scissors/hand) were statistically indistinguishable. Overall the 353 
splitting device produced the lowest weight loss but even with this method a weight loss as high 354 
as 26.6% was recorded when halving commercial metformin tablets. For digoxin tablets 355 
maximum weight loses of 37.0 and 37.6% were recorded using the scissors/hand and knife 356 
respectively (Verrue et al, 2010). Following subdivision of a novel fixed dose combination tablet 357 
capable of subdivision into 8 sub-units, weight loss was low (<0.4%) and independent of the 358 
subunit size (Kayitare et al, 2009). 359 
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These losses compare with those described by Green et al (2010) who discussed potential USP 360 
standards for the subdivision of scored tablets and indicated that to comply the mean loss of mass 361 
should not exceed 3% 362 
Bioavailability 363 
There were nine studies identified, all with adult participants, where modified-release tablets 364 
were split or crushed but, although the whole dose of the tablet was administered, the outcomes 365 
were considered relevant due to the potential to alter the drug release characteristics of the 366 
formulation Eight of these nine eligible studies were sustained-release formulations and one 367 
study used an enteric-coated formulation. 368 
Crushing of pentoxfylline extended-release (Trental) 400mg and 600mg tablets (Cleary et al, 369 
1999) and theophylline matrix sustained-release (Theo-Dur) 300mg tablets (MacKintosh et al, 370 
1985) did not significantly change the bioavailability, though the time taken to reach peak 371 
concentration was shorter with crushed tablets than with intact tablets. 372 
Five studies halved modified release tablets. No differences were found in bioavailability for 373 
halved and intact theophylline sustained-release (Theo-Dur) 100 mg tablets (Simons et al, 1982) 374 
and 300 mg tablets (Fagerström, 1980). One study used theophylline slow-release anhydrous 375 
(Uniphyllin®) 400 mg tablets (Primrose et al, 1983) and peak drug levels were significantly 376 
higher with halved than with intact tablets. Two studies used verapamil sustained-release 240 mg 377 
matrix tablets (McEwen et al, 1989; Moreland et al, 1989) and both studies found no differences 378 
in bioavailability for halved and intact tablets. One study involved cutting isosorbide-5-379 
mononitrate tablets into thirds and found no significant differences in bioavailability though 380 
maximum peak concentration was higher with the trisected tablets than with intact tablets 381 
(Stockis et al, 2002). Ferron et al (2003) crushed enteric-coated tablets (pantoprazole 40 mg) and 382 
found that the resultant suspension was 25% less bioavailable than the whole tablet. 383 
Two other studies were identified. There was no significant difference in pharmacokinetic 384 
parameters in a bioavailability study using adults between Duovir® and a novel fixed dose 385 
combination tablet, containing 300mg zidovudine and 160mg lamivudine, intended for paediatric 386 
HIV patients (Kayitare et al, 2009). Corbett et al (2010) manipulated a product to obtain a 387 
proportion of the original dosage form. This involved 18 HIV-infected children who received 388 
quartered, halved or three quartered generic tablet multiples of lamivudine (3TC) 300mg, 389 
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stavudine (d4T) 80 mg and nevirapine (NVP) 400 mg or a generic liquid or trade liquid in a 390 
crossover study. There was no significant difference in bioavailability between the different 391 
formulations and the time to maximum concentration was delayed for d4T and 3TC for the 392 
manipulated tablets compared with the liquid formulations. 393 
Evidence of safety or harms, adverse effects: 394 
Adverse effects considered to be related to the drug manipulation were relevant to this review. 395 
There were marginally more adverse effects reported in five of the nine bioavailability studies of 396 
modified release tablets with nausea/vomiting (Cleary et al, 1999; Primrose et al, 1983) and 397 
headache (Cleary et al, 1999; Primrose et al, 1983; Stockis et al, 2002) with crushed or split 398 
tablets than intact tablets. Two studies reported excellent tolerability with both split and intact 399 
tablets (Kayitare et al, 2009; Moreland et al, 1989). The one study which split enteric-coated 400 
tablets found both treatments to be well tolerated and considered the adverse effects reported to 401 
be related to nasogastric tube insertion rather than drug-related (Ferron et al, 2003). The number 402 
of adverse effects reported was small and conclusions cannot be drawn about whether 403 
manipulated medicines had more associated adverse effects. 404 
Patient experience: 405 
One study considered the experiences of children taking an oral solution compared with those 406 
taking a dispersion of crushed prednisolone tablets (Lucas-Bouwman et al, 2001). Taste assessed 407 
by visual analogue scores was significantly better for the oral solution than for the crushed 408 
tablets. Nine of the 78 children in the study also withdrew due to repeated vomiting while taking 409 
the crushed tablets. 410 
There were a further five surveys identified that assessed adult participants‟ experiences of 411 
splitting tablets. Three studies used the same questionnaire or an adapted version of it for tablets 412 
split with a tablet splitter. Carr-Lopez et al (1995) surveyed 233 patients (all 55 years old, or 413 
older) splitting lovastatin, Gee et al (2002) surveyed 454 patients (average age 66 years old) 414 
enrolled in a statin splitting programme and Fawell et al (1999) surveyed patients (median age 65 415 
years old) splitting fosinopril. Across the three studies, a small percentage of respondents (4% 416 
(Fawell et al, 1999), 6.3% (Lopez et al, 1995), 7% (Gee et al, 2002)) felt that using the tablet 417 
splitter had an effect on their willingness to take the drug as prescribed. Some respondents (7% 418 
(Gee et al, 2002), 6% (Fawell et al, 1999), 14% (Lopez et al, 1995)) reported having missed 419 
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more split tablet doses in a month when compared to other medicines where the tablet did not 420 
have to be halved. One study surveyed 99 patients, the majority of whom were 50 years old or 421 
older, with hyperlipidaemia who used a tablet splitter and found that more than 90% agreed that 422 
they found that tablet splitting had no t affected their willingness to take their medication and 423 
that 90% disagreed that they had missed more medication doses because of tablet splitting (Choe 424 
et al, 2007). In a survey of 28 patients, described as outpatient veterans, splitting lisinopril 425 
(method of splitting not reported) (Rindone, 2000), tablet splitting was bothersome „most‟ of the 426 
time for 25% of participants; for „some‟ of the time there were more than two pieces of the tablet 427 
following splitting for 54%, of the participants. 428 
Adherence:  429 
Three identified studies considered aspects of adherence for 57 participants splitting fosinopril 430 
tablets (Fawell et al, 1999) and 111 (Choe et al, 2007) or 3787 participants splitting statin tablets 431 
(Parra et al, 2005) with a tablet splitter. There were no differences in adherence between those 432 
splitting tablets and those taking whole tablets whether self-reported (Choe et al, 2007), 433 
measured by tablet counting, refill history and self-reporting (Fawell et al, 1999) or prescription 434 
refills (Parra et al, 2005). A fourth study, which included patients with schizophrenia or 435 
schizoaffective disorder splitting risperidone, found that adherence increased with tablet splitting 436 
(Weissman & Dellenbaugh, 2007). 437 
Effectiveness 438 
Tablets containing a statin have been frequently given as split tablets and clinical assessment 439 
made. No significant difference in total cholesterol, HDL, LDL or triglycerides between baseline 440 
levels and post splitting levels were found following split atorvastatin, simvastatin or pravastatin 441 
(Choe et al, 2007). In another study no significant difference in total cholesterol and triglycerides 442 
pre and post tablet splitting but significant small increases in HDL, AST and ALT and decreases 443 
in LDL were noted following the administration of split atorvastatin, lovastatin or simvastatin 444 
tablets (Gee et al, 2002). No significant difference in LDL between whole and halved tablets was 445 
found following administration of 5, 10, 20, or 40 mg simvastatin (Parra et al, 2005). Overall – 446 
significant decreases in total cholesterol and LDL pre and post splitting of simvastatin or 447 
atorvastatin (doses not specified) with half tablet dosing as effective as whole tablet taking 448 
(Duncan et al, 2002). For other classes of drugs, no significant difference in mean systolic and 449 
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mean diastolic blood pressure with tablet splitting of lisinopril was measured (Rindone, 2000) 450 
and no change in psychiatric or non-psychiatric admission rate was noted following the 451 
administration of splitting Risperidone tablets (Weissman & Dellenbaugh, 2007). 452 
Direct observational study from the literature: 453 
Mercovich et al (2014) reported observations of manipulation of solid oral dosage forms during 454 
medicine rounds in aged care facilities. From 160 observations across six medication rounds, 29 455 
residents had a total of 75 medications modified by the nursing staff prior to administration, with 456 
32% of these instances identified as inappropriate. Methods used for crushing and administration 457 
resulted in drug mixing, spillage and incomplete dosing. Staff reported adequate resources but a 458 
lack of knowledge on how to locate and use resources was evident. Mercovich et al (2014) 459 
concluded that improved staff training on how to use available resources was needed to reduce 460 
the observed high incidence of inappropriate modifications. 461 
Non-tablet studies: 462 
There were no studies identified through the systematic review which considered the 463 
manipulation of capsules, sachets, liquids for oral administration, nebuliser solutions, 464 
intravenous injections and injections for subcutaneous administration, enemas or transdermal 465 
patches. There was one study (Kim et al, 2005) identified through the systematic review which 466 
considered the manipulation of suppositories. This study asked anaesthesiologists to split 467 
paracetamol suppositories using the technique they would use in practice. This resulted in wide 468 
variation from the intended dose: intended dose 40 mg (range 30-78 mg), 53 mg (range 27-79 469 
mg), 60 mg (range 47-82 mg), 80 mg (range 38-92 mg), 162 mg (range 112-250 mg), and 217 470 
mg (range 113-259 mg)). The study concluded that the lack of accuracy and precision was a 471 
reason to use unaltered suppositories.  472 
GENERAL DISCUSSION  473 
This review has demonstrated that there is a dearth of evidence to support the widespread 474 
practice of drug manipulation in children. Where evidence was located it almost universally 475 
related to the manipulation of tablets for treating adult patients, with only one study which used 476 
any other dosage form. Only two studies had child participants (Corbett et al, 2010; Lucas-477 
Bouwman et al, 2001) and, in one of these (Lucas-Bouwman et al, 2001), the taste scores of 478 
crushed tablets were considered. In the other study (Corbett et al 2010), the formulations were 479 
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well tolerated and 10% of children commented on the enjoyable taste of the liquid formulations. 480 
Splitting tablets was frequently unreliable. The clinical consequences of this finding are difficult 481 
to estimate but are likely to be important in medicines with a narrow therapeutic index. When 482 
splitting tablets, it is reasonable to expect that the weight or drug content of segments will vary 483 
no more than would be expected for intact tablets. Pharmacopoeial standards for intact tablets are 484 
well established and usually include tests to establish uniformity of weight or content. When 485 
many of these studies were undertaken there were no pharmacopoeial standards for the quality of 486 
segmented tablets. Most authors adapted the criteria and methodology for testing the uniformity 487 
of intact tablets. Whilst the detail of tests may vary they are essentially ensuring low variability 488 
of weight and/or drug content between dosage units and the absence of outliers. In 2002 the 489 
European Pharmacopoeia presented pharmacopoeial standards for the subdivision of scored 490 
tablets. These standards, which marked the first time this type of pharmacopoeial requirement 491 
was established, have been subsequently reviewed and revised (Green et al, 2010). The use of 492 
such standards within other pharmacopoeias has been discussed and a  stimulus article discussed 493 
why standards should be included in the USP (Green et al, 2010) and are currently found in, for 494 
example, the British Pharmacopoeia (2016). Here, the efficacy of the break-mark(s) must be 495 
assessed during the development in respect of uniformity of mass of the subdivided parts where 496 
the selected tablets were broken by hand. Many of the citations in this study utilized tablet 497 
splitters or knives in the subdivision of tablets and their use has been broadly scientifically 498 
unestablished. 499 
The results identified in this review varied but the majority of studies suggest a lack of 500 
uniformity of segment weight or drug content when splitting tablets into halves and even greater 501 
variation when splitting in to quarters. Such lack of uniformity is unacceptable for intact „whole‟ 502 
tablets. When weight and content uniformity were tested, of concern is that when weight 503 
uniformity was compliant content uniformity often was not, suggesting uneven drug distribution 504 
within some tablets. Although there were few comparisons there would appear to be differences 505 
in variability of segments between different tablet strengths and between branded and generic 506 
tablets. The clinical importance of unequal splitting of tablets cannot be estimated: Only one 507 
study was identified that reported bioavailability after a proportion of a tablet (an antiretroviral) 508 
had been administered to children. In all other bioavailability studies relevant to this review 509 
sustained release tablets were split or crushed and the whole dose administered. Though there 510 
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were only nine studies using ten sustained release products there is an indication from four 511 
studies that there may be an effect on the intended modified drug release mechanism and 512 
consequently on bioavailability following manipulation. Reduction in the time to reach peak 513 
concentration was the outcome predominantly affected by the tablet being halved or crushed 514 
prior to administration. The modified release mechanism is important in determining whether the 515 
release characteristics will be altered upon splitting. 516 
Although results were inconsistent, tablets split using a tablet splitter were more likely to yield 517 
segments that had split more accurately than those split using methods including scissors, knife 518 
or manual splitting. Similarly scored tablets tended to provide segments closer to the intended 519 
weight. While these results can only be considered applicable directly to the products in the 520 
studies involved they do nonetheless suggest that use of a commercial tablet splitter and scored 521 
tablets may be beneficial if tablets must be split. 522 
In general the segmenting of tablets does not appear to affect adherence in adults although the 523 
evidence is based on a limited number of drugs. We found only one study that had paediatric 524 
participants and this considered the taste and tolerance of crushed tablets rather than other 525 
aspects of manipulation (Lucas-Bouwman et al, 2001). This study concluded that the oral 526 
solution was better tolerated than the crushed tablets. The only study of a dosage form other than 527 
tablets showed substantial variation in size of the segments cut from paracetamol suppositories 528 
by anaesthetists leading the authors to conclude that such suppositories should not be split. 529 
This study sought the evidence for an area of medical and nursing practice that could potentially 530 
include any drug and/or dosage form and therefore may be limited by its complex nature. We 531 
had specified that the only study type restrictions were on case series/studies, consequently 532 
included studies were heterogeneous not only in design and quality, but in terms of types of 533 
manipulations, drug types, dose forms, participants and outcomes investigated. Letters and case 534 
series excluded from this review may have included some of the anecdotal information on 535 
manipulation of dosage forms other than tablets and suppositories. It is also possible that clinical 536 
outcomes have been reported as case series or letters. For example, a letter suggesting 537 
satisfactory outcomes with split tablets of bosentan used for children with pulmonary 538 
hypertension followed an article and letter criticising the lack of information provided on the 539 
method of administration of bosentan tablets to young children (Rosenzweig et al, 2005). 540 
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Subsequently, regulatory submissions have included a formulation of bosentan tablets which is a 541 
quadrisected dispersible tablet containing 32 mg of bosentan to be dispersed in a teaspoon with 542 
water (EMA Report, 2012). Such regulatory reports were also not the subject of this review and 543 
individual summaries of product characteristics were not searched for information. 544 
What emerges from this review is that there is little published information on manipulation of 545 
dosage forms to achieve the required dose and further work is needed to support what is a 546 
common practice (Berg & Ekedahl, 2010). The majority of the included studies related to tablets 547 
and it is difficult to draw firm conclusions from the outcomes since the products and method of 548 
manipulation varied considerably as did the outcomes in terms of compliance with standards for 549 
variability derived from those for intact tablets.  550 
An optimum requirement would be studies where a drug was manipulated to obtain the required 551 
dose, administered to participants and outcomes reported. There were no studies identified which 552 
used this approach in children, the nearest being the study of Kayitare et al (2009) who 553 
developed a novel fixed dose combination tablet capable of subdivision to subunits containing a 554 
dose suitable for each 5 kg body weight. Biological characteristics were however established in 555 
adults. 556 
Each formulation of each drug may provide different results when manipulated. Consequently 557 
the planning of future research becomes challenging. This may be aided by the identification of 558 
drugs which frequently require manipulations and represent a higher risk if an over or under dose 559 
is administered (such as those with a narrow therapeutic index (Shah et al, 2010) or where the 560 
adverse effects of a manipulated drug might be a concern or by the recognition of patient groups 561 
where a number of the commonly prescribed drugs may require manipulation. The use of 562 
standardised research methodologies would help to build a more comprehensive resource of 563 
evidence relating to drug manipulation to aid clinical decision-making. 564 
No studies were identified that considered physical/chemical/microbial stability or contamination 565 
of the areas of manipulation.  566 
Subsequent to the completion of data searching in August 2015, two publications were noted that 567 
considered drug manipulation in children. Mistry and Batchelor (2016) highlighted the need for 568 
support knowledge around the acceptability of age-appropriate medicines and presented an 569 
algorithm to aid in formulation selection based on age range. Andersson et al (2016) concluded 570 
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that tablets larger than 8 mm could be split only once to achieve an approximate half dose for 571 
paediatric use. The authors could not recommend that tablets be split more than once due to a 572 
lack of weight uniformity of the part tablets after splitting. Both Mistry and Batchelor (2016) and 573 
Andersson et al (2016) concluded that more age-appropriate dosage forms, including small 574 
tablets, should be available to children. Andersson et al (2016) considered that non-functional 575 
score lines should be avoided since both patients and health professionals falsely believed that a 576 
score line indicates the possibility of dividing the tablet in two equal parts.  577 
A change in the manufacturing process of 10 mg hydrocortisone tablets, where an increased 578 
compression was used, led to reports (Saimbi et al, 2016) that the newer, harder tablets were 579 
more difficult to manipulate. Tablets were either manipulated by breaking along score lines to 580 
produce halved or quartered segments or 2mg doses were prepared by dispersing crushed tablets 581 
in 10 mL of water and taking a 2 mL aliquot; crushing was accomplished using a spoon onto a 582 
plate or a commercial crushing device (Saimbi et al, 2016). The harder tablets showed a better 583 
accuracy of split with weight ranges of 41 – 55% and 17 – 35% for halves and quarters 584 
respectively compared with weight ranges of 29–70% and 12–42%) for the less hard tablets. 585 
Conversely, the 2 mg dosing accuracy was better for both sets of tablets. The use of spoon / plate 586 
or the commercial device led to mean doses of 1.3 mg and 1.9 mg for the harder tablets and 1.7 587 
mg and 2.1mg for the less hard tablets. The authors concluded that parents or carers should be 588 
advised to crush the tablet into a fine powder, where possible, to improve dosage accuracy.  589 
Nidanapu et al (2016) used caregivers to split tablets containing anti-epileptic drugs (phenytoin 590 
sodium, sodium valproate, carbamazepine and phenobarbitone) intended for adults but 591 
prescribed to paediatric patients. The caregivers performed the same splitting process that they 592 
normally followed in their homes. 168 caregivers participated and 1098 split tablets were 593 
analysed. In total 49.0% of the split parts were above the specified limit of the 2010 Indian 594 
Pharmacopeia (IP) for acceptable percentage weight deviation. 41.5% of the split parts were 595 
outside a specification for drug content. 253 split parts were outside the acceptable content 596 
uniformity range of >85% and <115%.  597 
It is clear from the results in this paper that recommendations for the manipulation of products 598 
for children have to be advised by practices used in adults. Earlier iterations of the work 599 
described in this paper, in conjunction with other studies (Richey et al, 2012, 2013a, 2013b) were 600 
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used to develop a guideline (Manipulation of Drugs Required in Children (MODRIC)) for health 601 
professionals with recommendations for the Pharmaceutical Industry and regulators. Such 602 
recommendations include the need for the Pharmaceutical Industry to note the lack of evidence 603 
relating to the manipulation of medicines for the purposes of achieving a suitable dose for 604 
administration to children and to support practitioners in their requests for information around 605 
manipulations of medicines by recognising that children may require a range of doses that 606 
require manipulation of adult dosage forms. Regulatory authorities must recognise that 607 
manipulation is being undertaken in the paediatric population despite the lack of evidence and 608 
encourage the industry to provide evidence where reasonable and available. 609 
 610 
CONCLUSION 611 
Extensive searching yielded limited evidence to support the widespread clinical practice of 612 
manipulation of drugs with the aim of achieving the required dose. There is a need to conduct 613 
research about the impact of manipulation for dosage accuracy in all age groups. Future research 614 
should prioritise areas such as drugs with a narrow therapeutic index or clinical areas such as 615 
neonates or paediatric intensive care that are high risk because of manipulations, and should 616 
conduct standardised assessments of those manipulations. Where manipulations are a predictable 617 
use of a licensed product the effects of manipulations need to be included in drug development 618 
programmes.  619 
620 
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Table 1: Criteria used to describe the three quality levels used in this study 837 
Quality level Criteria 
++ Included studies where the reported methods and subsequent results and 
conclusions could be considered (with reasonable confidence) not to be 
biased. The process of the drug manipulations was at least adequately 
described. 
+ included studies where there were some concerns about the reported study 
methods or the methods were not reported with enough detail to permit 
sufficient assessment 
- included studies where there were considerable concerns about the reported 
methods or there was insufficient reporting of the methods for them to be 
assessed 
 838 
839 
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Table 2.  The quality ratings of the reported studies  840 
Reference Quality Reference Quality 
Boggie et al (2004) + McEwen et al (1989) - 
Broadhurst et al (2008) + Mercovich et al (2014) ++ 
Carr-Lopez et al (1995) + Moreland et al (1989) + 
Choe et al (2007) + Parra et al (2005) - 
Cleary et al (1999) ++ Polli et al (2003) ++ 
Cook et al (2004) ++ Powers & Cascella (1990) + 
Corbett et al (2010) + Primrose et al (1983) + 
Costa et al (2000) + Rashed et al (2003) + 
Duncan et al (2002) + Rindone (2000) + 
Erramouspe & Jarvi (1997) + Rosenberg et al (2002) + 
Fagerström (1980) - Shah et al (1987) + 
Fawell et al (1999) + Simons et al (1982) + 
Ferron et al (2003) ++ Stimpel et al (1985) + 
Footitt (1983) + Stockis et al (2002) + 
Gee et al (2002) - Tahaineh & Gharaibeh (2012) ++ 
Habib et al (2014) ++ Teng et al (2002) + 
Helmy (2015) ++ Tuleu et al (2005) + 
Hill et al (2009) ++ van Riet-Nales et al (2014) ++ 
Horn et al (1999) + van Vooren (2002)  - 
Kayitar et al ++ Verrue et al (2010) + 
Kim et al (2005) - Vranic & Uzunovic (2008) + 
Lucas-Bouwman et al (2001) - Walker et al (1978) + 
MacKintosh et al (1985) + Weissman & Dellenbaugh (2007) + 
Mandal (1996) + Williams et al (2002) - 
McDevitt et al (1998) + Zaid & Ghosh (2011) ++ 
 841 
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Table 3 Studies which halved or quartered tablets and used pharmacopoeial-based outcomes for weight and/or drug content uniformity 842 
Drugs Outcomes summary Ref 
One scored and one unscored product Both products did not meet the BP uniformity of weight specification  Footitt (1983) 
Six products 
2 scored, oblong, non-coated, scored 
2 oval, film-coated, unscored 
1 circular, non-coated, scored  
1 oval, non-coated, unscored 
43/180 (23.9%) of half tablets were outside of USP specification for drug 
content. 
 23/180 (12.8%) of half tablets were outside USP specification for weight 
22.2% (20/90) of scored tablets were outside the USP specification for drug 
content compared with 25.6% (23/90) unscored tablets 
11.1% (10/90) of scored tablets were outside the USP specification for weight 
compared with 14.4% (13/90) unscored tablets 
Hill et al (2009) 
Twelve products 
2 oval, unscored 
1 oval, scored 
3 round, scored  
1 trapezoid, unscored  
1  unscored 
2 oblong, scored 
1 shield-like, unscored 
1 round/spherical, unscored. 
8/12 halved products passed adapted USP weight uniformity test; 6 out of 
these 8 products were scored.  
4/12 did not pass adapted USP uniformity test; lovastatin, Each of these 4 
products was unscored. 
Polli et al (2003) 
Five products 
Three unscored 
Two scored on one side 
Tablets halved. 
Only one of the two scored products met the USP weight specification. 
Rashed et al (2003) 
22 products 
1 ovoid-rectangular, scored 
5 capsule-shaped, scored 
1 round, unscored 
8  round, scored 
1 oblong, scored 
Halved tablets. 
 
6 scored and 1 unscored product met the USP weight specification including 
the extended release product 
13 scored and 2 unscored products did not meet the USP weight specification;  
Rosenberg et al (2002) 
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1 elliptical, scored 
1 biconvex, scored, extended-release 
1 modified-oval, scored 
2 oblong, unscored 
1 shield-shaped, scored  
11 Products 
3  oval, not flat, unscored 
1 oval, not flat, scored  
2 not oval, not flat, scored  
1 not oval, flat, scored 
4 not oval or flat, unscored 
Halved tablets. 
 
3 products met the USP weight variation specification; one product was 
scored and two were oval 
8 Products did not meet USP weight variation specification; of these three 
were scored and two were oval 
Teng et al (2002) 
One sustained-release round 
unscored,  product 
38/40 tablet halves deviated from the percentage deviation allowed by the 
European Pharmacopoeia for uncoated or film-coated tablets of ≤80mg). 
There was wide variability for half and quarter tablet weights 
Tuleu et al (2005) 
14  scored products were studied 
4 products were oblong of which 2 
were film coated. 
10 products were round 
 
Halved tablets 
 
Only one film coated, oblong product met the European Pharmacopoeia 
specification for weight uniformity of scored tablets. 
The remaining 13 products A following splitting had fragments outside of the 
85-115% range of the average mass 
Only four tablets following splitting (one film coated oblong; one oblong and 
two round had no fragments outside of the 75-125% range of the average 
mass  
Zaid & Ghosh (2011) 
 843 
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Table 4. The influence of cutter on the halving and quartering of 7 tablet products on the % halves or 844 
quarters weighing within ±15%, USP specification. 3 lots of each product were used and the range across 845 
these lots is indicated (Taken from Horn et al, 1999) 846 
  847 
 % halves or quarters weighing within ±15% 
 Halves Quarters Halves Quarters 
Product First cutter; First cutter; Second cutter Second cutter 
clonidine (brand 52.5-100% 43.8-60% 85-90% 57.5-71.3% 
clonidine (generic) 47.5-70% 37.5-45% 30-78.9% 25.0-48.8% 
Captopril 58.3-95% 37.5-55% 95-100% 26.3-36.1% 
Amlodipine 77.5-85.7%  76.9-90.5%  
Atenolol 62.5-95%  27.5-35%  
Sertraline 100%  90-100%  
Carbamazepine 87.5-92.5%  60-80%  
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Table 5: Summary of the twelve studies that compared the splitting of tablets using different techniques 848 
Observations Ref 
8 products were examined. Tablets split with a tablet splitter had significantly lower deviation from theoretical 
weight and significantly less weight loss than those split by scissors (unscored)/hand (scored) or with a kitchen 
knife. There was no significant difference in weight between the scissors/hand and the kitchen knife. There was 
significantly less weight loss with the scissors/hand than with the kitchen knife. 
Verrue et al (2010) 
A razor blade based cutting apparatus resulted in quarters where a large proportion were outside acceptable 
limits for uniformity of weight; non-uniformity was more marked with tablets broken by hand  
Walker et al (1978) 
Of 11 products halved with a razor blade, 3 passed USP uniformity of weight specification (2 unscored; 1 
scored) and 8 failed ((5 unscored; 3 scored). 3 of the scored products  which failed the uniformity specification 
when split with a razor blade, also failed when split by hand 
Teng et al (2002) 
Two commercial splitters were examined for halving and quartering tablets of 6 different drugs. Neither splitter 
yielded consistent results for tablet quarters or halves.  
Horn et al (1999) 
No significant difference between 100 unscored tablets halved with a tablet splitter and 25 tablets of the same 
drug which were split by hand 
Boggie et al (2004) 
Halves of round, film coated, unscored tablets, halved with a tablet splitter showed that 16% had a deviation of 
>15% from the theoretical weight compared with 58% of tablets were split with a kitchen knife 
Cook et al (2004) 
33% of manually halved round, scored tablets but 40.2% tablet splitter halved tablets and were within 5% of the 
ideal weight 
McDevitt et al (1998) 
2 methods of crushing whole tablets for nasogastric tube administration (pestle/mortar and between medicine 
cups) and dispersing whole tablets showed significant differences in the amount of drug delivered. Suspending 
the drug in the syringe delivered 18% more drug than crushing with medicine cups and 36% more than crushing 
with pestle and mortar. 
Powers & Cascella 
(1990) 
No significant difference in mean fragment weight was found between round unscored tablets quartered with a 
tablet splitter or manually cut with a razor blade. There was a significantly greater variance within the group 
produced from the tablet splitter than that quartered with the manually split tablets. 
Williams et al (2002) 
Flat, round, cross-scored tablets were manually halved and quartered, using four different tablet orientations or 
split using a knife. Fracturing to halves, the score-up orientation gave the lowest residual variance. The score-
down orientation and the score-up knife halved tablets had the lowest person variability. The score-down break 
had significantly higher variability than for score-up break or score-up knife orientations for quartered tablets 
van Vooren (2002)  
Tablets (round, flat, uncoated) were divided by hand or using 6 different proprietary tablet splitters or a kitchen 
knife. Only hand split half-tablets complied with weight requirements 
van Riet-Nales et al 
(2014) 
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A tablet splitter was superior to manual splitting in halving scored salbutamol tablets. Drug content variation in 
half-tablets appeared to be attributable to weight variation occurring during splitting. 
Habib et al (2014) 
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literature 
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